Integrin alpha V beta 8

Integrin alpha V beta 8

Integrin alpha V beta 8 분자 정보

Molecule Name
integrin alpha V/beta 8
분자 별명
Integrin alpha V beta 8,ITGAV&ITGB8
Drug Development Progress
임상 약물 수3
시판 약물 수0
최고 연구 개발 단계Phase 2 Clinical
표적 별명
alphavbeta8 integrin
분자 배경
Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Integrin alpha V beta 8 제품 목록

Species
  • Cynomolgus(2)
  • Human(2)
  • Mouse(2)
  • Rat(1)
Tag
  • His Tag(4)
  • His Tag & Avi Tag(3)
Host
  • HEK293(7)
Conjugate
  • Unconjugated(4)
  • Biotin-labeled(3)
Grade
  • RUO(7)
Low Endotoxin
  • Yes(1)
  • No(6)
You Have Viewed 1-7 Of 7 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
NesvategrastSF-0166; OTT-166(OcuTerra Therapeutics)Phase 2 ClinicalOcuTerra Therapeutics Inc, Scifluor Life Sciences Inc
Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration
상세
CRB-601CRB-601Phase 2 ClinicalCorbus Pharmaceuticals Holdings Inc, Uc San Francisco
Solid tumours
상세
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics Inc
Solid tumours
상세
Customer Reviews